P-PPI-L 15 Capsules

Babies: It does not apply to babies. Lactating mothers: Levosulpiride and pantoprazole capsule is considered unsafe in lactating mothers.
Studies suggest that drug passes into breast milk may cause toxicity to the baby. Consult your doctor before taking this medication. Pregnancy: Levosulpiride, and pantoprazole capsule, is unsafe to use during pregnancy.
However, take it if prescribed by your doctor. Consult your doctor before taking this medication.
Alcohol: Avoid alcohol consumption while taking this medication, as alcohol may increase the side effects of this medicine. Kidney: Levosulpiride and pantoprazole capsules should be used with caution in kidney disease patients.
Dose adjustment may be needed. Consult your doctor before using this medication.
Liver: Levosulpiride, pantoprazole capsules should be used with caution in liver disease patients. Dose adjustment may be needed.
Consult your doctor before using this medication..

Stomach pain Vomiting Diarrhea Headache Nausea Flatulence Dizziness.

P-ppi-l works by blocking the action of a proton pump, which is responsible for acid production. It also works by increasing the pressure of the food pipe, thereby prevents the backflow of food and acid into the mouth..

If you miss a dose, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• P-ppi-l capsule is prescribed to give relief from acidity and its associated symptoms. • Avoid smoking and spicy foods. • Take it 1 hour before the food in the morning time most preferably on an empty stomach. • Inform your doctor if you get watery diarrhoea or stomach pain. • Avoid alcohol while taking this medication as it may increase the risk of stomach damage. • Prolonged use may lead to weak or broken bones. Take adequate intake of dietary calcium and vitamin D or their supplements.

• Pantoprazole + Rilpivirine: Concurrent use of these drugs may result in reduced rilpivirine plasma concentration and diminished therapeutic effect of rilpivirine. • Pantoprazole + Acalabrutinib: Concurrent use of these drugs may result in reduced acalabrutinib exposure. • Pantoprazole + Dasatinib: Concurrent use of these drugs may result in decreased dasatinib concentration. • Pantoprazole + Infigratinib: Concurrent use of these drugs may result in decreased infigratinib plasma concentration. • Pantoprazole + Iron: Concurrent use of these drugs may result in reduced iron bioavailability. • Pantoprazole + Ponatinib: Concurrent use of these drugs may result in decreased ponatinib efficacy..